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requiring medical assistance (DC= 6.0, DT= 5.9), HE requiring non-medical assistance 
(DC= 5.9, DT= 5.9), other HE not requiring assistance (DT= 5.7), and treatment goals 
not being met (DC= 5.6). Compared to current users, DT and DC patients were more 
likely to have experienced ≥ 1 HE in the previous year (DC= 41.0%, DT= 43.1% vs. 
current= 8.8%; p< .05), and experienced a greater mean number of events per year 
(DC= 1.59, DT= 1.47 vs. current= 0.24, p< .05). Having ≥ 1 HE requiring medical assis-
tance in the previous year was more common among DC patients than DT or current 
patients (DC= 7.4%, DT= 4.3%, current= 4.8%; p< .05). CONCLUSIONS: Hypoglycemia 
and glycemic control emerged as the most important concerns physicians have 
when deciding to DC or DT SU therapy. DC and DT patients were more likely to have 
experienced HE, and with greater severity, than current SU patients.
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OBJECTIVES: While change in glycated hemoglobin (A1C) is typically used as the 
primary measure of efficacy in clinical trials of diabetes medications, quality of care 
in “real-world” clinical practice is often assessed based on attainment of patient-
specific A1C targets, as recommended in HEDIS 2014 performance benchmarks by 
the National Committee for Quality Assurance. HEDIS measures are used by US 
health plans to measure care and service performance. To assist in the design of 
pragmatic clinical trials for new insulin glargine 300 U/ml (Gla-300), we estimated 
A1C targets for T2DM patients initiating basal insulin in real-world clinical prac-
tice, using a large retrospective database and data from a clinical trial. METHODS: 
Insulin-naïve T2DM patients initiating basal insulin were identified in both the 
Ingenix Impact National Managed Care (IMPACT) database (n= 22,428) and EDITION 
3 (n= 862), a clinical trial of Gla-300. Patients were stratified according to whether 
they were aged < 65y and free of selected comorbidities (A1C target < 7.0%), or aged 
≥ 65y and/or with one or more comorbidities (A1C target < 8.0%), according to HEDIS 
measures. RESULTS: In the IMPACT database, mean age was 52y, and mean baseline 
A1C (SD) was 9.0% (±2.7) in those with available A1C. Patients aged < 65y without 
comorbidities (target < 7.0%) constituted 68.1% of the sample, while 31.9% were 
aged ≥ 65y and/or had comorbidities (target < 8.0%). In the EDITION 3 trial, mean age 
was 58y, and mean baseline A1C (SD) was 8.5% (±1.1). Patients aged < 65y without 
comorbidities (target < 7.0%) constituted 73.0%, and 27.0% were aged ≥ 65y and/or 
had comorbidities (target < 8.0%). CONCLUSIONS: The distribution of T2DM patients 
initiating basal insulin by A1C target, based on HEDIS performance measures, was 
similar in both real-world and clinical trial settings. Findings from trials therefore 
may be useful in the design of pragmatic clinical trials of Gla-300.
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OBJECTIVES: The aim of the study was to measure the effect of diabetes educational 
program on type 2 diabetic patients. METHODS: In total, a convenient sample of 
215 patients were attended a group-based educational intervention session about 
diabetes which is conducted by a researcher. Knowledge evaluation questionnaire 
were evaluated at pre and post test. Anthropometric measurements and lab tests 
were measured at pre and post test. Significance of the results was assessed by 
paired t- test at 95% confidence interval using SPSS version 16. RESULTS: BMI was 
decreased significantly after educational intervention, (from 32.1±5.76 to 31.23±5.8) 
(p = 0.000). Moreover, a significant decrease in glycosylated hemoglobin after edu-
cational intervention were reported, (from 8.57± 1.21 to 7.95±1.42) (p = 0.000).A sig-
nificant increase in knowledge evaluation test scores were shown after educational 
intervention (from 60.6±20.65 increased to 78.1±13.4) (p = 0.000). CONCLUSIONS: 
Diabetes education is a cornerstone in the management and care of diabetes and 
should be an integral part of health planning involving patient’s family, diabetes 
care team, community and decision makers in the education process.Key words 
Diabetes, Educational, Program, Intervention.
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OBJECTIVES: It is important to understand diabetes treatment patterns over time. 
This study compared changes in comorbidities, treatment patterns, and costs 
among newly-diagnosed T2D patients in 2007 and 2012. METHODS: Separate 
cross-sectional analyses of medical treatments, diagnoses, and pharmacy claims 
in the Truven Health MarketScan® Database were conducted for 2007 and 2012. 
Criteria for newly-diagnosed T2D were enrolment 6 months prior to index, ≥ 2 
diagnoses for T2D (ICD-9 codes), ≥ 18 years old, and continuous enrolment in 
a plan with prescription benefits for ≥ 1 year. RESULTS: Comparing 2007 with 
2012, T2D incidence rate decreased from 1.1% to 0.65% of all enrolled patients. 
Hyperlipidemia (46% and 57%) and hypertension (55 % and 62%) were the 2 most 
prevalent comorbidities. 46% and 57% of patients in 2007 and 2012 used only oral 
anti-diabetic drugs (OADs). Single OAD use increased from 68% to 77% of these 
patients. Metformin (Met) was the most prevalent OAD monotherapy, amounting 
to 75% and 90% of single OAD prescriptions. SU monotherapy fell from 14% to 6%. 
Met+SU, the most widely used dual OAD combination, grew from 48% to 57% of 
dual users. Met+TZD use fell from 30% to 0%, replaced by Met+DPP-IV (34%). An 
insulin-only regimen was used by 1.4% and 1.6% of patients for 2007 and 2012, 
and insulin+OADs were used by 2.5% and 3.7% of patients, respectively. Basal 
HealthCoin ≥ PCure - EINMBNE, Private , where INMBMedicare is the incremental 
net monetary benefits (INMB) to Medicare of a cure of diabetes for a 65-years old, 
EINMBNE, Private is the average INMB to the private payer for a cure of diabetes 
across all non-elderly incident population with diabetes, and PCureis the market 
price for the cure. Using empirical estimates, we explore whether a developing 
such a HealthCoin would be feasible. CONCLUSIONS: We find, theoretically, that 
developing such a HealthCoin may be feasible for a cure of diabetes. Extension of 
this work would explore how such HealthCoins can be traded within the private 
sector and also in other disease areas.
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OBJECTIVES: Women with Gestational Diabetes Mellitus (GDM) have six times higher 
risk of developing Diabetes Mellitus (DM) type 2 compared to women who don’t have 
GDM. The purpose of this study was to evaluate the protective effects of breast-feeding 
on development of DM in women with GDM. METHODS: This was a cross sectional 
study where a secondary database analysis was done using National Health and 
Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010 and 2011-2012. 
Females 20 to 75 years with at least one live birth were included. Chi-square-test 
compared differences between categorical variables and t-test examined differences 
in the means for continuous variables. Unadjusted-odds-ratio was calculated using 
logistic regression to examine breastfeeding as an effect modifier in the association 
between GDM and DM. Model was adjusted for age, BMI, race/ethnicity, income, edu-
cation, age at DM and number of live births. Sample weights and the stratification 
and clustering of the design were incorporated to obtain proper estimates. RESULTS: 
The final analytic sample consisted of 6503 participants. Percentage of GDM women 
who breast-fed seemed higher than women without GDM (64.6 % vs. 44.9%). Among 
women who breastfed, the odds ratio for developing DM in women with GDM was 
3.3 (95% CI 2.3, 4.9) compared to those without GDM while, in women who never 
breastfed, the odds ratio was 3.9 (95% CI 2.3, 6.6). After adjusting for age, BMI, race/
ethnicity, education and number of live births, OR for the association between DM and 
GDM was 2.2 (1.4, 3.4) in women who breastfed and 2.8 (1.6, 4.9) in women who didn’t 
breast feed. CONCLUSIONS: This analysis found that there’s potential benefit of BF 
in the prevention of DM among women who had GDM. This result adds to the already 
known important benefits of BF and more women should be encouraged to BF.
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OBJECTIVES: Most endocrine disorders are chronic diseases that need life-long 
care. Some of the most common endocrine diseases include diabetes mellitus, 
hypothyroidism and metabolic syndrome. Although most of the patients suffering 
of these diseases are followed by their primary care physician, definite diagno-
sis, initiation/change of treatment and chronic care of the disease is ensured by 
the endocrinologist. The objective of this study was to evaluate an endocrinolo-
gist electronic medical record (EMR) database to assess its feasibility for use in 
observational studies. METHODS: We analyzed de-identified patient data from 
Longitudinal Patient Database (LPD) Endocrinologist panel, including endocrinolo-
gists from 2013-2014. Comprehensiveness and completeness of each variable by 
visit was evaluated. Characteristics of physicians and patient population were 
compared to published sources. RESULTS: There were 77 243 visits by 34 492 active 
patients (= 1 visit per year) to 40 physicians. Completeness of each variable by visit 
ranked from 100% to 27% for sex, age and laboratory results. Most of these patients 
(73%) were female. Analysis of diagnosis associated to visits revealed that 32 % 
were related to diabetes, while 32% and 9% were related to thyroid disorders and 
obesity respectively. Among diabetic patients, 50% were female, and 74% had type 
2 diabetes. An average BMI of 30 and HbA1C of 7.4% was recorded. Among treated 
patients 38% received sulfonylureas and 59 % biguanides. A third of the patients 
(34%) received one, another third (33%) received two, and another third (33%) three 
or more anti-diabetic treatments (including insulin). Insulin was prescribed, alone 
or in combination, in 36% of cases. The comparison of these data with literature 
is presented. CONCLUSIONS: This panel is still new and needs further validation 
studies. Good agreement with published data suggests this may be a valuable tool 
to support observational studies.
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OBJECTIVES: Sulfonylureas (SU) are a widely-prescribed class of oral medications 
used to treat type 2 diabetes mellitus and are known to cause hypoglycemic events 
(HE) and weight gain. In this survey, we aimed to identify reasons reported by physi-
cians for discontinuing (DC) or down-titrating (DT) SU therapy. METHODS: Primary 
care physicians (PCPs) and specialists (endocrinologists and diabetologists) were 
recruited from the AllGlobal panel, an actively managed, double opt-in panel of 
physicians. Participants were asked to rate their level of concern regarding potential 
reasons for DC or DT on a 7-point Likert scale (1= not at all concerned, 7= extremely 
concerned). In addition, physicians reviewed one chart each from a typical SU 
patient with DC or DT in the previous 6 months and 2 current SU patients without 
DC or DT in the previous 6 months to collect patient characteristics and medical 
history. RESULTS: 776 PCPs and 250 specialists participated, of whom 76% were 
male and 93% were aged 35 to 64. Physicians reported highest concern about HE 
